Research ExplorerPublicationsPeptide fingerprinting of Alzheimer's disease in cerebrospin...

Peptide fingerprinting of Alzheimer's disease in cerebrospinal fluid: identification and prospective evaluation of new synaptic biomarkers.

Standard

Peptide fingerprinting of Alzheimer's disease in cerebrospinal fluid: identification and prospective evaluation of new synaptic biomarkers. / Jahn, Holger; Wittke, Stefan; Zürbig, Petra; Rädler, Thomas; Arlt, Sönke; Kellmann, Markus; Mullen, William; Eichenlaub, Martin; Mischak, Harald; Wiedemann, Klaus.

In: PLOS ONE, Vol. 6, No. 10, 10, 2011, p. 26540.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Jahn, H, Wittke, S, Zürbig, P, Rädler, T, Arlt, S, Kellmann, M, Mullen, W, Eichenlaub, M, Mischak, H & Wiedemann, K 2011, 'Peptide fingerprinting of Alzheimer's disease in cerebrospinal fluid: identification and prospective evaluation of new synaptic biomarkers.', PLOS ONE, vol. 6, no. 10, 10, pp. 26540. https://doi.org/10.1371/journal.pone.0026540

APA

Jahn, H., Wittke, S., Zürbig, P., Rädler, T., Arlt, S., Kellmann, M., Mullen, W., Eichenlaub, M., Mischak, H., & Wiedemann, K. (2011). Peptide fingerprinting of Alzheimer's disease in cerebrospinal fluid: identification and prospective evaluation of new synaptic biomarkers. PLOS ONE, 6(10), 26540. [10]. https://doi.org/10.1371/journal.pone.0026540

Vancouver

Jahn H, Wittke S, Zürbig P, Rädler T, Arlt S, Kellmann M et al. Peptide fingerprinting of Alzheimer's disease in cerebrospinal fluid: identification and prospective evaluation of new synaptic biomarkers. PLOS ONE. 2011;6(10):26540. 10. https://doi.org/10.1371/journal.pone.0026540

Bibtex

@article{84c599e0971642b697a64439f0e26d2b,
title = "Peptide fingerprinting of Alzheimer's disease in cerebrospinal fluid: identification and prospective evaluation of new synaptic biomarkers.",
abstract = "Today, dementias are diagnosed late in the course of disease. Future treatments have to start earlier in the disease process to avoid disability requiring new diagnostic tools. The objective of this study is to develop a new method for the differential diagnosis and identification of new biomarkers of Alzheimer's disease (AD) using capillary-electrophoresis coupled to mass-spectrometry (CE-MS) and to assess the potential of early diagnosis of AD.",
keywords = "Adult, Diagnosis, Differential, Humans, Male, Aged, Female, Middle Aged, Young Adult, Sensitivity and Specificity, Case-Control Studies, Mass Spectrometry, Alzheimer Disease/*cerebrospinal fluid/*diagnosis, Artificial Intelligence, Biological Markers/cerebrospinal fluid, Electrophoresis, Capillary, Nerve Tissue Proteins/*analysis, *Peptide Mapping, Proteomics/methods, Synapses/*chemistry, Adult, Diagnosis, Differential, Humans, Male, Aged, Female, Middle Aged, Young Adult, Sensitivity and Specificity, Case-Control Studies, Mass Spectrometry, Alzheimer Disease/*cerebrospinal fluid/*diagnosis, Artificial Intelligence, Biological Markers/cerebrospinal fluid, Electrophoresis, Capillary, Nerve Tissue Proteins/*analysis, *Peptide Mapping, Proteomics/methods, Synapses/*chemistry",
author = "Holger Jahn and Stefan Wittke and Petra Z{\"u}rbig and Thomas R{\"a}dler and S{\"o}nke Arlt and Markus Kellmann and William Mullen and Martin Eichenlaub and Harald Mischak and Klaus Wiedemann",
year = "2011",
doi = "10.1371/journal.pone.0026540",
language = "English",
volume = "6",
pages = "26540",
journal = "PLOS ONE",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "10",

}

RIS

TY - JOUR

T1 - Peptide fingerprinting of Alzheimer's disease in cerebrospinal fluid: identification and prospective evaluation of new synaptic biomarkers.

AU - Jahn, Holger

AU - Wittke, Stefan

AU - Zürbig, Petra

AU - Rädler, Thomas

AU - Arlt, Sönke

AU - Kellmann, Markus

AU - Mullen, William

AU - Eichenlaub, Martin

AU - Mischak, Harald

AU - Wiedemann, Klaus

PY - 2011

Y1 - 2011

N2 - Today, dementias are diagnosed late in the course of disease. Future treatments have to start earlier in the disease process to avoid disability requiring new diagnostic tools. The objective of this study is to develop a new method for the differential diagnosis and identification of new biomarkers of Alzheimer's disease (AD) using capillary-electrophoresis coupled to mass-spectrometry (CE-MS) and to assess the potential of early diagnosis of AD.

AB - Today, dementias are diagnosed late in the course of disease. Future treatments have to start earlier in the disease process to avoid disability requiring new diagnostic tools. The objective of this study is to develop a new method for the differential diagnosis and identification of new biomarkers of Alzheimer's disease (AD) using capillary-electrophoresis coupled to mass-spectrometry (CE-MS) and to assess the potential of early diagnosis of AD.

KW - Adult

KW - Diagnosis, Differential

KW - Humans

KW - Male

KW - Aged

KW - Female

KW - Middle Aged

KW - Young Adult

KW - Sensitivity and Specificity

KW - Case-Control Studies

KW - Mass Spectrometry

KW - Alzheimer Disease/cerebrospinal fluid/diagnosis

KW - Artificial Intelligence

KW - Biological Markers/cerebrospinal fluid

KW - Electrophoresis, Capillary

KW - Nerve Tissue Proteins/analysis

KW - Peptide Mapping

KW - Proteomics/methods

KW - Synapses/chemistry

KW - Adult

KW - Diagnosis, Differential

KW - Humans

KW - Male

KW - Aged

KW - Female

KW - Middle Aged

KW - Young Adult

KW - Sensitivity and Specificity

KW - Case-Control Studies

KW - Mass Spectrometry

KW - Alzheimer Disease/cerebrospinal fluid/diagnosis

KW - Artificial Intelligence

KW - Biological Markers/cerebrospinal fluid

KW - Electrophoresis, Capillary

KW - Nerve Tissue Proteins/analysis

KW - Peptide Mapping

KW - Proteomics/methods

KW - Synapses/chemistry

U2 - 10.1371/journal.pone.0026540

DO - 10.1371/journal.pone.0026540

M3 - SCORING: Journal article

VL - 6

SP - 26540

JO - PLOS ONE

JF - PLOS ONE

SN - 1932-6203

IS - 10

M1 - 10

ER -